The glucagon-like peptide 1 receptor (GLP-1R) 6 and the glucagon receptor (GCGR) are class B G protein-coupled receptors (GPCRs) involved in insulin release and glucose homeostasis, respectively. Accordingly, they have attracted extensive attention for their importance as targets for therapeutic intervention of type 2 diabetes (1, 2). Class B GPCRs consist of an N-terminal extracellular domain (ECD) linked to a seven-transmembrane helical (7TM) region. Studies examining truncated, chimeric, and mutated ligand and receptor variants together with multiple ligand-bound ECD crystal structures and two class B 7TM domain crystal structures are consistent with a "two-domain" binding mechanism for peptide hormone ligands to the secretin-like class B GPCRs (3-5). According to this peptide ligand binding mechanism, the C terminus of the peptide hormone forms an initial complex with the ECD, allowing the N terminus of the ligand to interact with the 7TM domain. It is the N-terminal interactions that ultimately result in activation of the receptor and stimulation of downstream coupling to G proteins and other effectors that mediate intra-*